NCT06919003View on ClinicalTrials.gov

Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)

PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

September 22, 2025

Primary Completion Date

May 30, 2031

Study Completion Date

May 30, 2032

Conditions
Kidney Transplant
Interventions
BIOLOGICAL

Berinert

Administered as a 10 ml renal artery infusion approximately 1-2 hours before implantation and reperfusion of the allograft

OTHER

Placebo for Berinert

Administered as a 10 ml renal artery infusion approximately 1-2 hours before implantation and reperfusion of the allograft

Trial Locations (4)

60611

RECRUITING

Northwestern Memorial Hospital, Chicago

66160

RECRUITING

Kansas University Medical Center, Kansas City

90048

RECRUITING

Cedars Sinai Medical Center, Los Angeles

10467-2401

RECRUITING

Montefiore Medical Center, The Bronx

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT06919003 - Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL) | Biotech Hunter | Biotech Hunter